These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10321505)

  • 1. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.
    Boccardo F; Rubagotti A; Amoroso D; Agostara B; Amadori D; Gallo L; Iacobelli S; Massidda B; Mesiti M; Pacini P; Tomao S; Paganuzzi M; Marroni P
    Cancer Chemother Pharmacol; 1999; 43(6):461-6. PubMed ID: 10321505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group].
    Untch M
    Zentralbl Gynakol; 1998; 120(6):284-92. PubMed ID: 9659699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer.
    Dowsett M; Jacobs S; Aherne J; Smith IE
    Clin Ther; 1992; 14 Suppl A():97-103. PubMed ID: 1606596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
    Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
    J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review.
    Kendzierski DC; Schneider BP; Kiel PJ
    Clin Breast Cancer; 2018 Oct; 18(5):e939-e942. PubMed ID: 29747931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence on hormone levels, lipid metabolism and reversibility of endocrinological changes after leuprorelin acetate depot therapy.
    Bühler K; Winkler U; Schindler AE
    Clin Ther; 1992; 14 Suppl A():104-13. PubMed ID: 1606590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.
    Masuda N; Iwata H; Rai Y; Anan K; Takeuchi T; Kohno N; Takei H; Yanagita Y; Noguchi S
    Breast Cancer Res Treat; 2011 Apr; 126(2):443-51. PubMed ID: 21221770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.
    Aydiner A; Kilic L; Yildiz I; Keskin S; Sen F; Kucucuk S; Karanlik H; Muslumanoglu M; Igci A
    Med Oncol; 2013 Mar; 30(1):354. PubMed ID: 23275115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
    Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.
    Brown CS; Ling FW; Andersen RN; Farmer RG; Arheart KL
    Obstet Gynecol; 1994 Nov; 84(5):779-86. PubMed ID: 7936512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estradiol suppression and recovery during leuprolide acetate treatment in women as determined weekly by an ultrasensitive recombinant cell bioassay.
    Larmore KA; Klein KO
    Gynecol Endocrinol; 2000 Dec; 14(6):405-10. PubMed ID: 11228060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot.
    Dumesic DA; Matteri RL
    Int J Fertil Menopausal Stud; 1993; 38(3):139-46. PubMed ID: 8348161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study.
    Cirkel U; Ochs H; Schneider HP; Mettler L; Mayer-Eichberger D; Schindler AE; Bühler K; Winkler U; Zahradnik HP; Künzig HJ
    Clin Ther; 1992; 14 Suppl A():37-50. PubMed ID: 1606593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study].
    Schindler AE; Bühler K; Gerhard I; Wiedemann R; Kimmig R; Schüssler B; Kranzfelder D; Mall-Häfeli M; Meinen K; Mancarella D
    Zentralbl Gynakol; 1994; 116(12):679-86. PubMed ID: 7846980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study.
    Kurebayashi J; Toyama T; Sumino S; Miyajima E; Fujimoto T
    Breast Cancer; 2017 Jan; 24(1):161-170. PubMed ID: 27017207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study.
    Crosignani PG; De Cecco L; Gastaldi A; Venturini PL; Oldani S; Vegetti W; Sémino A; La Commare P; Vercellini P
    Hum Reprod; 1996 Dec; 11(12):2732-5. PubMed ID: 9021380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.